SLRN Overview

Merger Approval: ACELYRIN, Inc. announced that its stockholders approved the merger agreement with Alumis Inc., where ACELYRIN shareholders will receive 0.4814 shares of Alumis common stock for each share they own, with completion expected in Q2 2025.

Future Outlook: CEO Mina Kim expressed confidence that the merger will maximize value by combining their complementary pipelines, while also highlighting potential risks and uncertainties associated with the merger process.

Merger Approval: Alumis Inc. announced that its stockholders approved all proposals related to its pending merger with ACELYRIN, INC., with the merger expected to close in the second quarter of 2025.

Company Focus: Alumis is a clinical-stage biopharmaceutical company developing therapies for immune-mediated diseases, leveraging a precision data analytics platform to enhance treatment outcomes.

Merger Approval: Alumis Inc. announced that its stockholders approved all proposals related to its pending merger with ACELYRIN, INC., with the merger expected to close in the second quarter of 2025.

Company Overview: Alumis is a clinical-stage biopharmaceutical company focused on developing oral therapies for immune-mediated diseases, utilizing a precision data analytics platform to enhance treatment outcomes.

ACELYRIN's Proposed Merger: ACELYRIN, INC. is urging stockholders to vote in favor of its proposed merger with Alumis Inc., following a recommendation from the independent proxy advisory firm ISS that supports the transaction as beneficial for maximizing shareholder value.

Upcoming Vote and Context: The special meeting for stockholders to vote on the merger is scheduled for May 13, 2025, with ISS highlighting uncertainties regarding alternative options and the potential risks associated with liquidation, thus reinforcing the strategic rationale for the merger.

Special Meeting Announcement: ACELYRIN, Inc. has scheduled a special meeting for stockholders on May 13, 2025, to vote on the proposed merger with Alumis Inc., urging stockholders to vote in favor of the transaction to maximize their investment value.

Board's Confidence in Merger: The ACELYRIN Board unanimously recommends the merger, highlighting that it will create a leading clinical-stage immunology company and provide significant potential upside for stockholders, who would retain approximately 48% ownership in the combined entity.

Merger Agreement Update: ACELYRIN stockholders will now own approximately 48% of the combined company with Alumis, following a revised exchange ratio in their merger agreement aimed at maximizing value for both parties.

Investor Presentation and Meeting: ACELYRIN has filed an investor presentation detailing the benefits of the merger, and a Special Meeting of Stockholders for both companies is scheduled for May 13, 2025, to discuss the transaction.